Bicara Therapeutics (NASDAQ:BCAX) CEO Claire Mazumdar Sells 15,000 Shares

Bicara Therapeutics Inc. (NASDAQ:BCAX) CEO Claire Mazumdar sold 15,000 shares of the firm’s stock in a transaction dated Monday, April 20th. The stock was sold at an average price of $23.61, for a total value of $354,150.00. Following the completion of the sale, the chief executive officer directly owned 362,152 shares in the company, valued at $8,550,408.72. The trade was a 3.98% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Claire Mazumdar also recently made the following trade(s):

• On Wednesday, March 18th, Claire Mazumdar sold 6,499 shares of Bicara Therapeutics stock. The shares were sold at an average price of $18.84, for a total value of $122,441.16.
• On Thursday, March 19th, Claire Mazumdar sold 6,905 shares of Bicara Therapeutics stock. The stock was sold at an average price of $18.78, for a total value of $129,675.90.
• On Friday, March 20th, Claire Mazumdar sold 1,596 shares of Bicara Therapeutics stock. The stock was sold at an average price of $18.95, for a total value of $30,244.20.
• On Monday, March 9th, Claire Mazumdar sold 36,766 shares of Bicara Therapeutics stock. The shares were sold at an average price of $19.17, for a total value of $704,804.22.
• On Friday, March 6th, Claire Mazumdar sold 3,817 shares of Bicara Therapeutics stock. The shares were sold at an average price of $18.75, for a total value of $71,568.75.
• On Wednesday, March 4th, Claire Mazumdar sold 2,631 shares of Bicara Therapeutics stock. The stock was sold at an average price of $18.73, for a total value of $49,278.63.
• On Thursday, March 5th, Claire Mazumdar sold 1,786 shares of Bicara Therapeutics stock. The shares were sold at an average price of $18.74, for a total transaction of $33,469.64.

Bicara Therapeutics Trading Down 2.2%

Shares of Bicara Therapeutics stock opened at $23.47 on Tuesday. Bicara Therapeutics Inc. has a 12-month low of $7.80 and a 12-month high of $24.25. The company has a market cap of $1.54 billion, a P/E ratio of -9.28 and a beta of -1.23. The company’s fifty day simple moving average is $18.82 and its two-hundred day simple moving average is $17.64.

Bicara Therapeutics (NASDAQ:BCAX) last announced its earnings results on Monday, March 30th. The company reported ($0.68) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.72) by $0.04. Analysts predict that Bicara Therapeutics Inc. will post -2.72 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research firms have recently commented on BCAX. The Goldman Sachs Group raised their target price on Bicara Therapeutics from $14.00 to $16.00 and gave the company a “neutral” rating in a research note on Tuesday, March 31st. Bank of America began coverage on Bicara Therapeutics in a report on Wednesday, March 25th. They issued a “buy” rating and a $35.00 price objective for the company. BTIG Research reissued a “buy” rating on shares of Bicara Therapeutics in a research report on Thursday, January 15th. Wedbush restated an “outperform” rating and set a $30.00 target price on shares of Bicara Therapeutics in a report on Tuesday, March 31st. Finally, Citigroup started coverage on shares of Bicara Therapeutics in a research report on Thursday, January 29th. They issued an “outperform” rating on the stock. Eight equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $28.00.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Caitong International Asset Management Co. Ltd lifted its position in Bicara Therapeutics by 385.3% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 5,775 shares of the company’s stock valued at $97,000 after acquiring an additional 4,585 shares in the last quarter. T. Rowe Price Investment Management Inc. boosted its position in shares of Bicara Therapeutics by 596.5% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 3,236,595 shares of the company’s stock valued at $54,472,000 after buying an additional 2,771,868 shares during the last quarter. Invesco Ltd. increased its holdings in Bicara Therapeutics by 20.6% in the 4th quarter. Invesco Ltd. now owns 21,006 shares of the company’s stock worth $354,000 after buying an additional 3,595 shares in the last quarter. VARCOV Co. bought a new stake in Bicara Therapeutics in the 4th quarter worth about $263,000. Finally, Virtus Investment Advisers LLC raised its position in Bicara Therapeutics by 46.4% in the 4th quarter. Virtus Investment Advisers LLC now owns 14,395 shares of the company’s stock worth $242,000 after buying an additional 4,560 shares during the last quarter.

Bicara Therapeutics Company Profile

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.